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Background: Demoralization syndrome is a significant condition that has not been
greatly studied in Southern European countries.
Aims: To extend the knowledge of demoralization in Southern Europe by examining
its prevalence according to different methods of assessment, its relationship with
anxiety and depression, and its impact on quality of life (QoL) among cancer patients.
Methods: A convenience sample of 195 cancer outpatients from two oncology
centers (102 from Lisbon, Portugal, and 93 from Ferrara, Italy) participated in an
observational, cross‐sectional study using the Diagnostic Criteria of Psychosomatic
Research‐Demoralization interview (DCPR/D) and psychometric tools (Demoraliza-
tion scale‐DS; Patient Health Questionnaire–9/PHQ‐9; Hospital Anxiety Depression
Scale‐HADS; and European Quality of Life‐5‐EQ‐5D).
Results: A 25.1% prevalence (CI 95%, 0.19‐0.31) of clinically relevant demoralization
was reported on the DCPR/D interview. A total demoralization score cutoff score ≥ 25
maximized sensitivity (81.6%), and specificity (72.6%) in identifying DCPR/D
demoralized patients. The DCPR/D and DS were associated with poorer levels of
QoL. About half of the patients who were demoralized were not clinically depressed
(PHQ‐9). Self‐reported suicidal ideation (PHQ‐9 item 9) was found in a minority of
patients (8.2%), most of whom (77%) were cases of depression (PHQ‐9), but one‐quar-
ter (23%) were not depressed, yet moderately/severely demoralized (DCPR/D and DS).
Conclusions: This Southern European study confirms the importance of demoraliza-
tion in cancer patients as a different condition with respect to depression and its rela-
tionship with poor QoL and suicidal ideation.
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Demoralization, as introduced by Frank, is a syndrome of existential dis-
tress denoting a persistent failure of coping, with internally or externallywileyonlinelibrary.induced stress, and typically occurring in patients with severe condi-
tions that threaten life or integrity of being.1 Demoralization has been
more specifically described as a mental state of subjective incompe-
tence,2 and, in agreement with Kissane et al3 and Clarke and Kissane,4Psycho‐Oncology. 2018;27:2616–2622.com/journal/pon
NANNI ET AL. 2617it is a syndrome, with a 15% to 30% prevalence,5-7 a duration of more
than 2 weeks, encompassing several existential and psychological
dimensions (eg, hopelessness or loss of meaning and purpose in life;
pessimism, helplessness, sense of being trapped or personal failure).
In medical settings, especially in oncology and palliative care, a
diagnosis of demoralization has been found to be distinct from major
depression,8-10 yet to have negative consequences on patients' quality
of life (QoL),11 coping styles, and dignity.12 Very importantly, it is also
associated with higher demand for a hastened death13 and frank
suicidal ideation, after controlling for other mental disorders, including
self‐reported depression.14,15 Existential and meaning‐centered psy-
chotherapy approaches are gradually emerging as specific for demoral-
ization and its symptoms, rather than for major depression.16,17
Relatively few data have been available from Southern Europe.
Two Italian studies showed a 28% prevalence of demoralization in
breast cancer patients18 and a relationship between demoralization
and poor QoL, maladaptive coping, and worries about cancer.19 A
cross‐sectional Portuguese study showed a higher prevalence of
demoralization (52.5%) in a sample of 80 terminally ill cancer patients,
with comorbidity of demoralization and depression20 in 30%. In 226
palliative care patients in Spain, high anxiety was associated with
greater demoralization.21
Given this background, the aims of the present study were to
extend the knowledge of demoralization in two Southern European
countries, Italy and Portugal, by examining (1) its prevalence compar-
ing a categorical structured clinical interview with a dimensional self‐
report measure and (2) its relationship with QoL and psychological
variables, among cancer patients in two countries, Italy and Portugal,
within a larger European psychosocial oncology study.222 | SUBJECTS AND METHODS
2.1 | Subjects
A convenience sample of cancer outpatients participated in a cross‐
sectional, observational study that was conducted in two centers,
the Unit of Clinical Oncology, University Hospital S. Anna, Ferrara
(Italy), and the Oncology Department of the Centro Hospitalar de Lis-
boa Central, Lisbon (Portugal), during a period of 6 months. Criteria for
inclusion were ages between 18 and 70 years, cancer diagnosis in all
stages of disease, and good knowledge of their native language. Exclu-
sion criteria were presence of severe cognitive impairment (MMSE
score ≤ 24) and Karnofsky Performance Rating Scale score ≤ 50.
Attention was paid to having patients fulfil the same criteria at the
two centers. The study was approved by the ethical committee or
related boards of each hospital. Each patient was informed about the
aims of the study, gave his/her written consent to participate, and
was individually met by research clinicians in the two units trained in
psycho‐oncology, who administered a semi‐structured interview and
a psychometric battery during a single session.2.2 | Assessment
Demoralization was examined by means of two different instruments,
the Diagnostic Criteria for Psychosomatic Research‐Demoralizationinterview (DCPR/D) and a self‐report scale that is the Demoralization
Scale (DS). The categorical diagnosis of demoralization by the DCPR/D
enables calculation of clinically relevant threshold scores on the DS,
which no study has yet done.
Quality of life was measured through the European Quality of
Life‐5 (EQ‐5D), psychological variables consisted of depression and
anxiety, as assessed by the Patient Health Questionnaire‐9 (PHQ‐9),
and the Hospital Anxiety Depression Scale (HADS).
The DCPR/D is part of a larger semi‐structured clinical inter-
view,23 with a diagnosis made if the following criteria are met: (1) fail-
ure to meet one's own expectations and/or those of others; (2)
inability to cope with some pressing problems; (3) helplessness/hope-
lessness, or giving up; and (4) duration of the condition ≥1 month. The
DCPR/D has been used in large samples of medically ill and cancer
patients, and it has been proposed as a “gold standard” for the assess-
ment of demoralization.8,15,16,24
The DS25 is a 24‐item self‐report tool on 5‐point Likert scale
(“never” = 0; “all the time”=4), based on the original criteria developed
by Kissane (Table S1). The scale, used in its validated Italian and
Portuguese versions,20,26 had four subscales (disheartenment; loss of
meaning/purpose; dysphoria; sense of failure) in factorial analysis,
with good (DS‐Disheartenment, IT: α = 0.9, PT: α = 0.89; DS‐Loss of
meaning, IT: α = 0.81, PT: α = 0.80; total demoralization score
(DS‐Total), IT: α = 0.89, DS‐Total PT: α = 0.89) or acceptable (DS‐
Dysphoria, IT: α = 0.72; PT: α = 0.75; DS‐Sense of failure, IT:
α = 0.71, PT: α = 0.79) levels of internal consistency (Cronbach α). A
DS‐Total is obtained by summing item scores.
The EQ‐5D27 is a measure of health outcomes through five ques-
tions covering mobility, self‐care, usual activities, pain/discomfort, and
anxiety/depression, each scored on a 3‐point scale (1 = no problems;
3 = extreme problems). A Visual Analogue Scale (VAS) measures over-
all health (0 = worst imaginable health; 100 = best imaginable health).
Responses to these questions were both used as raw scores and, as
recommended, converted through a standardized scoring system, to
a single Health State Index (HSI) (range score 0‐1, higher score = better
QoL). The scale had been used in a European project involving the
countries participating in this study.28,29
The PHQ‐930 is derived from the PRIME‐MD and it is based on
the nine Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition criteria for major depressive disorder. Each item is rated on a
4‐point Likert scale (from 0 = not at all to 3 = nearly every day) over
the past 2 weeks. A threshold of ≥10 was used to identify cases of
depression. Cronbach α in this study had good (IT: α = 0.82, PT:
α = 0.89) levels of internal consistency. The scale had been used in a
previous Southern European psycho‐oncology study.31
The HADS32 is a 14‐item self‐reported instrument divided into
two subscales: HADS‐Anxiety (seven items) and HADS‐Depression
(seven items) (item responses on 0‐3 Likert scale, score range = 0‐21
each), and a HADS‐Total score yielded by summing the two subscales.
Cronbach α showed good levels of internal consistency (HADS‐Anxi-
ety, IT: α = 0.81, PT: α = 0.86; HADS‐Depression, IT: α = 0.80, PT:
α = 0.82; HADS‐Total, IT: α = 0.86; PT: α = 0.87). The scale had been
used in a previous Southern European psycho‐oncology study.33,34
The patients' socio‐demographic and medical information were
gathered from each patients' clinical chart.
TABLE 1 Socio‐demographic and clinical variables for Italian,










54.34 (9.9) 52.82 (11.03) 53.55 (10.51)
Education (yrs) 10.59 (3.78) 9.95 (4.49) 10.2 (4.2)
Sex
Male 29 (31.2%) 24 (23.5%) 43 (22.1%)
Female 64 (68.8%) 78 (76.5%) 152 (77.9%)
Marital status
• single 9 (9.7%) 13 (12.7%) 22 (11.3%)
• married 73 (78.5%) 74 (72.5%) 147 (75.4%)
2618 NANNI ET AL.2.3 | Statistical analysis
Distribution and frequency analyses were used to describe the sample.
Student t test, analysis of variance, and χ2 test where used to analyze
the differences between samples. Spearman's rho test was used to
test the correlation between the variables. The sensitivity, specificity,
positive predictive, and negative predictive values of different scores
on the DS in discriminating between demoralized cases and noncases
were examined by using the DCPR/D as a “gold standard.” Receiver
operating characteristic analysis was used to explore the optimal DS
cutoff score in detecting cases in our sample,35 with an area under
the curve value >0.80 considered as indicative of good discrimination.
Statistical analysis was carried out using the Statistical System Statis-
tical Package for Social Sciences (SPSS) in its version 17.• widowed 2 (2.2%) 3 (2.9%) 5 (2.6%)
• divorced 8 (8.6%) 12 (11.8%) 20 (10.3%)
• unknown 1 (1.1%) 0 (0) 1 (0.5%)
Occupation
• employed 47 (50.5%) 58 (56.8%) 105 (53.84%)
• retired 32 (34.4%) 30 (29.4%) 62 (31.8%)
• unemployed 7 (7.5%) 5 (4.9%) 12 (6.15%)
• housewife 6 (6.4%) 7 (6.8%) 13 (6.6%)
• unknown 1 (0.1%) ‐‐‐ 1 (0.1%)
Clinical Site
• breast 46 (49.4%) 67 (65.8%) 113 (57.9%)
• gastrointestinal 25 (26.9%) 26 (25.5%) 51 (26.2%)
• genitourinary 9 (9.7%) 10 (9.8%) 19 (9.7%)
• respiratory 9 (9.7%) 7 (6.8%) 16 (8.2%)
• other 4 (4.3%) 2 (1.9%) 6 (3.1%)
Stage
• local 32 (34.4%) 43 (42.15%) 75 (38.5%)
• loco‐regional 20 (21.5%) 28 (27.4%) 48 (24.6%)
• metastatic 41 (44.8%) 31 (30.4%) 72 (36.9%)3 | RESULTS
3.1 | Socio‐demographic and clinical characteristics
of the sample
Of 224 patients meeting the recruitment criteria and approached for
the study, 199 (88.4%) accepted and 25 declined to participate (13
from PT and 12 from IT: 17 reported that they were not interested
in the study, 5 did not have time to wait; 3 had other problems). No
difference was found between those who accepted and those who
declined participation. Of the former group, complete data were avail-
able for 195, 93 (47.7%) from Italy and 102 (52.3%) from Portugal,
with no significant differences between the two countries (Table 1).
The mean age was 53.44 (± 10.51) years. Most patients were female
(n = 152, 77.9%), married (n = 147, 75.4%), and employed (n = 105,
53.84%). Mean education was for 10.82 (±4.2) years. The majority of
patients (n = 113, 57.94%) had breast cancer, and local/loco‐regional
disease (n = 123, 63.1%).
Treatment
• surgery 81 (87%) 91 (89.2%) 172 (88.2%)
• chemotherapy 81 (87%) 86 (84.3%) 167 (85.6%)
• radiotherapy 41 (44%) 61 (59.8%) 102 (52.3%)
• hormone‐
therapy
49 (56.7%) 53 (51.9%) 102 (52.3%)3.2 | Demoralization according to the DCPR and DS
The mean DS‐Total was 24.74 (±13.38), with no difference between
the IT and PT cohorts (t = 0.3, P = ns). With respect to Italians, Portu-
guese patients reported lower scores on the subscale DS‐Dysphoria
(t = 3.1, P = .002), and higher scores on DS‐Failure (t = 2.89, P < .01)
and DS‐Loss of meaning/purpose (t = 3.5, P = .001) (Table S2).
Forty‐nine patients (25.1%; 24 IT, 25.8%; 25 PT, 24.5%) (CI
95%, 0.19‐0.31) met the DCPR/D criteria for demoralization, with
no difference between countries (χ2 = 0.043, df, 1; P = ns). DCPR/
D cases showed higher scores on all the DS subscales (all P < .001)
(Table 2). Further analyses were done following the procedure sug-
gested by Mullane et al36 and Robinson et al37 on the DS‐Total
score, with 13.9% to 26.3% patients resulting no/low, 68.6% to
51.5% moderately, and 18% to 22.2% severely demoralized, respec-
tively (Appendix S1).
Although some differences between the DCPR/D interview
criteria and the DS exist (eg, DCPR/D time frame = 1 month;
DS = 2 weeks), we conducted a receiver operating characteristic anal-
ysis, considering the interview as the gold standard. A DS‐Total cutoff
score ≥ 25 maximized the sensitivity and specificity in identifyingDCPR/D demoralized patients (40/49 = sensitivity 81.6%, CI, 70.8%‐
92.5%; 106/146 = specificity 72.6%, CI, 65.4%‐79.8%) (χ2 = 43.4; df,
1; P = .001). The positive predictive and negative predictive values
were 50% (40/80) and 92% (106/115), respectively (misclassification
rate = 25.1%, n = 49) (Figure 1).3.3 | Association between demoralization and QoL
DCPR/D+ patients had higher scores on EQ‐5D dimensions (raw
scores), the HSI, and the EQ‐5D/VAS (all P < .001) (Table 3). Correla-
tion analyses showed significant associations of all the DS subscales
and DS‐Total with EQ‐5 D‐Mobility and Anxiety/Depression, EQ‐
5D‐VAS, and HSI (rho between .19 and .55, P from <.01 to <.001).
EQ‐5D‐Pain/Discomfort was associated with DS‐Disheartenment
(rho = .31, P < .01) and DS‐Total (rho = .23, P < .01). EQ‐5D‐Usual









• Disheartenment 6.32 (5.95)* 11.95 (4.87)
• Loss of meaning 3.64 (4.32)** 5.81 (3.94)
• Failure 6.1 (3.9)*** 8.18 (3.2)
• Dysphoria 4.37 (3.24)**** 7.89 (3.47)
• Total 20.41 (12.52)***** 33.85 (10.63)
*t = 5.98, F = 35.74, P < .001;
**t = 3.22, F = 9.44, P = .02;
***t = 3.75, F = 11.53, P = .001;
****t = 6.23, F = 41.63, P < .001;
*****t = 7.25, F = 44.59, P < .001
NANNI ET AL. 2619Activities was associated with DS‐Disheartenment (rho = .33,
P < .001), DS‐Loss of meaning/purpose (rho = .21, P < .01), and DS‐
Total (rho = .31, P < .001) (Table S3).3.4 | Association between demoralization and other
psychological variables
DCPR/D+ or DS‐demoralized patients showed higher scores on HADS‐
Anxiety, HADS‐Depression, HADS‐Total, and PHQ‐9, with increasingFIGURE 1 Receiver operating characteristic
(ROC) analysis comparing the Diagnostic
Criteria of Psychosomatic Research‐
Demoralization (“gold standard”) versus the
Demoralization Scalescores according to increasing levels of demoralization (all P < .001)
(Tables 3 and S4). These scales were also significantly correlated with
all the DS‐subscales (rho from .42 to .78, P < .001) (Table S3).
On the PHQ‐9, 41 patients (21%) were classified as cases of
depression. Among this group, 26 (63.4%) were also DCPR/D+.
Twenty‐three (out of 49, 46.9%) were DCPR/D+ but not depressed,
and 15 (out of 146 DCPR/D‐, 10.3%) were depressed but not
demoralized (χ2=37.94, df, 1; P = .001). Self‐reported suicidal ideation
(score 2/3 on PHQ‐9 item 9) was reported by 16 patients (8.2%), of
whom 13 (77%) were PHQ‐9+, and 3 (23%) were PHQ‐9‐ but DCPR/
D+ or moderately/severely demoralized on the DS. Suicidal ideation
was associated with DS‐Disheartenment (rho = .30, P < .001) and DS‐
Loss of meaning/purpose (rho = .33, P < .001) more than DS‐Failure
(rho = .23, P < .01) and DS‐Dysphoria (rho = .15, P < .05).
3.5 | Association of demoralization with clinical
variables
No difference was found between males and females on any DS sub-
scale or DS‐Total. Patients with metastatic disease had higher scores
on the DS‐Disheartenment ( F = 8.53, df, 2; P = .01) and DS‐Total
( F = 4.35, df, 2; P = .01). Age was slightly correlated with DS‐Dyspho-
ria (rho = −.15, P = .03).
4 | DISCUSSION
In the present study, we examined demoralization among cancer
patients in two Southern European countries, Italy and Portugal.
TABLE 3 Differences on the quality of life and psychosocial vari-






HADS‐Anxiety 6.14 (3.27) 10.6 (3.1)**
HADS‐Depression 4.39 (3.7) 8.2 (4.12)**
HADS‐Total 10.53 (6.1) 18.83 (5.6)**
PHQ‐9 5.2 (4.12) 9.61 (4.13)**
EQ‐5D
• Mobility item 1.26 (0.44) 1.53 (0.58)**
• Self‐care item 1.1 (0.33) 1.24 (0.56)*
• Usual activities item 1.43 (0.6) 1.89 (0.65)**
• Pain/discomfort item 1.68 (0.53) 1.97 (0.52)**
• Anxiety/depression
item
1.63 (0.53) 2.1 (0.47)**
EQ‐5D Health State
Index (HSI)
0.6 (0.34) 0.26 (0.44)**
EQ‐5D VAS 66.73 (10.6) 53.54 (15.1)**
Abbreviations: DCPR/D, Diagnostic Criteria for Psychosomatic Research,
Demoralization module; EQ‐5D, European Quality of Life‐5; HADS,
Hospital Anxiety Depression Scale; PHQ‐9, Patient Health Questionnaire
for DSM‐IV depression.
* F = 4.14, P < .05.
** F = 9.18‐71.32, P < .01.
2620 NANNI ET AL.Our first main finding, in general agreement with most studies,
was that demoralization as assessed by the DCPR/D clinical interview
was diagnosable in one out of four patients. By using the DS‐Total
score, the percentage of patients with severe and moderate demoral-
ization (18%‐22% and 68.6%‐51.5%, respectively, according to two
different scoring systems36,37) was similar to that reported in palliative
care settings in other studies (eg, Germany: 15.7%, 73.1%10; Ireland:
14%, 68%36).
A further related finding was that DCPR/D+ patients had higher
scores on all the DS subscales measuring the several components of
these conditions, with only a few differences on some DS‐subscales
between Portuguese and Italian patients.
With the DCPR/D clinical interview as a “gold standard,” a cutoff
score ≥ 25 maximized the sensitivity (81.6%), and the specificity
(72.6%) of the DS in identifying DCPR/D+ patients. This cutoff is
lower than the cutoff ≥30 proposed by Kissane et al25 and used in
some other cross‐cultural studies in palliative settings.38 However,
no other authors have compared the DS with another demoralization
instrument, like the DCPR/D. A clear limitation was that the DCPR/D
uses a longer time framework (1 month vs 2 weeks in the DS) and it
does not examine phenomena like loss of meaning or dysphoria, which
is examined through five items in the DS.
A second significant main finding is that demoralization was
associated with poorer QoL. Physical (such as pain), functional, and
psychological symptoms, as measured by the EQ‐D5, were associ-
ated with demoralization. This confirms the few other studies from
Northern Europe reporting that demoralized cancer patients have
poorer levels of QoL,10,12,39 as already demonstrated also in patients
diagnosed with major depression.28,29The difference between the constructs of demoralization and
anhedonic depression, as reported in English‐speaking countries,12
was confirmed in our study. It is evident that some level of comorbid-
ity between demoralization and depression should be expected, just as
frequent comorbidity exists between anxiety and depression and
between demoralization and anxiety. In fact, we found significant cor-
relations between the DS and both the PHQ‐9 and the HADS‐Depres-
sion and Anxiety subscales. However, in line with previous studies
conducted both in medically ill patients9 and cancer patients,18 there
were also clear differences, as shown by the finding that almost half
of patients who were DCPR/D+ were shown to be not clinically
depressed.
We finally examined the association between demoralization and
self‐reported suicidal ideation (item 9 on the PHQ‐9). Although a
minority of patients reported having thoughts to commit suicide
(8.3%), one‐quarter of them were not clinically depressed on the
PHQ‐9 but were demoralized. This result is in general agreement with
a few studies that investigated this aspect,14,15 indicating that this
subgroup of patients with poor coping yet no major depression needs
an alternative diagnostic category to capture the phenomenology that
represents such serious symptomatology.4.1 | Study limitations
There are a number of limitations to our study. First, the large num-
ber of patients with breast cancer in comparison with other types of
cancer and the low number of male cancer patients indicates the
need for replication in samples of patients with more representative
cancer sites. Also, the characteristics of the sample (convenience
sample of outpatients with a good performance status) prevent us
from generalizing our results to other contexts, such as patients
admitted to the hospital and those with more advanced disease. A
further issue regards the fact that we should have explored a series
of important cultural factors (eg, religious affiliation, spirituality,
socioeconomic status, household income, living in suburb, or rural
area or city) to more precisely infer the possible role of cultural fac-
tors on demoralization when comparing the data of Northern versus
Southern European countries. The association between demoraliza-
tion and other dimensions, such personality traits, existential and
spiritual variables, and dignity is also necessary to have a more
specific characterization of the syndrome and the possible variables
influencing or predisposing to it.
Future research should explore possible expansion of the
DCPR/D semi‐structured interview to include some aspects that are
part of the demoralization syndrome, as defined by Kissane et al3
(eg, meaninglessness and dysphoric mood). Recently, Julião et al20
used Kissane's criteria in a categorical way to make the diagnosis of
demoralization in palliative care in Portugal, although caution is called
for regarding this interview, as it had not been specifically validated.
Alternatively, the development of a DCPR/D‐based psychometric tool
could be interesting to favor the assessment of psychological condi-
tions that are not part of the standard psychiatric nosology (such as
both demoralization and the other constructs measured by the DCPR).
Also, a new shorter version of the DS (DS‐II) that was not available at
the time of our study has been recently validated in Australia37,40
NANNI ET AL. 2621measuring demoralization through two parameters, Meaning/Purpose
and Distress/Coping Ability, and showing good psychometric proper-
ties. Studies comparing this new version could enlarge the interpreta-
tion of demoralization both from the clinical and the intervention point
of view.
4.2 | Clinical implications
The strength of this study is that it is the first examining a possible
correlation between the DS and a structured clinical interview for
demoralization, the DCPR/D, extending the knowledge of this syn-
drome and the need for a correct assessment. This reinforces the
significance of demoralization given its impact on several aspects
of the patients' QoL, including mental and physical health care.
Taking into account the negative consequences that demoralization
brings and the role of the cultural variables in the context of psy-
chological responses to a diagnosis of cancer, the results obtained
in the present study are helpful in deepening our understanding of
this issue in Mediterranean countries.
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